The Gulf did 400 healthcare deals, and healthtech is the next layer

The Gulf Cooperation Council recorded approximately 400 healthcare transactions between 2021 and April 2025, with the UAE leading at 198 and Saudi Arabia following at 170. That is a substantial volume of deal activity in a sector the region is actively building. Most of it has been in services and facilities rather than in technology. Those 400 transactions were largely hospital groups, clinic chains, laboratory networks, pharmacy consolidation and insurance. The Gulf's healthcare M&A market is one in which private equity buyers assemble regional operators and sell them to larger regional operators. That is a legitimate and profitable business, and the technology intensity of the assets traded is low — most are physical facilities running an electronic medical record system bought from an international vendor. The spending picture around it is large. The Saudi digital health market is estimated at $4.4bn in 2025, with more than $1.5bn of government allocation to healthcare IT. The UAE ecosystem was valued at $34bn in FY2024. The MENA medical device market runs from $24.6bn in 2025 toward $35bn by 2032. Most of that reaches international suppliers — Epic, Cerner, Philips, Siemens Healthineers and the systems integrators who deploy them — because a ministry procuring a national health record buys from a vendor with national health records already running elsewhere. That is the reference customer problem, and it is the main obstacle for regional healthtech. A company needs a comparable deployment to win a national contract, and the buyer's risk tolerance on a critical clinical system is, correctly, very low. Altibbi is the most instructive case. It raised a $44m Series B in 2023 and is widely described as the strongest candidate to become the region's first healthtech company at that scale. Its model — telehealth and health information in Arabic, aimed at consumers rather than institutions — routes around the procurement question entirely. It does not need a ministry to buy it. It needs patients. That looks like the most available path for regional healthtech now: build for the consumer and the private clinic, where the sales cycle is months rather than years and a reference deployment is not a prerequisite, and let institutional adoption follow demonstrated scale. The complementary route runs through procurement design — phased deployments that let a supplier prove a system in one region before national rollout, which is how a first reference deployment gets created without putting a national system at risk. Qatar's shift toward creating markets for its startups is the clearest regional example of a state using purchasing to solve exactly that problem.